The stock of Cardiol Therapeutics Inc (CRDL) has seen a 5.84% increase in the past week, with a 31.82% gain in the past month, and a 36.79% flourish in the past quarter. The volatility ratio for the week is 6.06%, and the volatility levels for the past 30 days are at 4.79% for CRDL. The simple moving average for the last 20 days is 6.66% for CRDL’s stock, with a simple moving average of 1.21% for the last 200 days.
Is It Worth Investing in Cardiol Therapeutics Inc (NASDAQ: CRDL) Right Now?
The 36-month beta value for CRDL is at 1.03. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CRDL is 78.70M, and currently, shorts hold a 2.53% of that float. The average trading volume for CRDL on June 26, 2025 was 200.98K shares.
CRDL) stock’s latest price update
Cardiol Therapeutics Inc (NASDAQ: CRDL)’s stock price has soared by 8.21 in relation to previous closing price of 1.34. Nevertheless, the company has seen a gain of 5.84% in its stock price over the last five trading days. newsfilecorp.com reported 2025-05-29 that Toronto, Ontario–(Newsfile Corp. – May 29, 2025) – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the “AGM”) held virtually via live audio webcast on May 28, 2025. Shareholders voted overwhelmingly in favour of all Management resolutions proposed in the Company’s Management Information Circular dated April 10, 2025.
Analysts’ Opinion of CRDL
Many brokerage firms have already submitted their reports for CRDL stocks, with H.C. Wainwright repeating the rating for CRDL by listing it as a “Buy.” The predicted price for CRDL in the upcoming period, according to H.C. Wainwright is $9 based on the research report published on June 02, 2025 of the current year 2025.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see CRDL reach a price target of $7. The rating they have provided for CRDL stocks is “Buy” according to the report published on January 28th, 2025.
ROTH MKM gave a rating of “Buy” to CRDL, setting the target price at $10 in the report published on June 26th of the previous year.
CRDL Trading at 20.99% from the 50-Day Moving Average
After a stumble in the market that brought CRDL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.87% of loss for the given period.
Stock Fundamentals for CRDL
The total capital return value is set at -1.05. Equity return is now at value -190.61, with -126.69 for asset returns.
Based on Cardiol Therapeutics Inc (CRDL), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -158.08.
Currently, EBITDA for the company is -29.59 million with net debt to EBITDA at 0.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.26.
Conclusion
In conclusion, Cardiol Therapeutics Inc (CRDL) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
